Novartis Venture Fund — 2023 Investments

2 investments dated 2023 · listed companies and verified rows first · show all

AstronauTX Ltdastronautx.bio inSeries A · Oct 2023 · $59M

AstronauTx is a biotechnology company focused on drug discovery and development for neurodegenerative and neuroinflammatory diseases, working across small molecules and biologics.

BiotechDeep TechHealthtechLongevityMedical Devices

Jane Rhodes(Chief Executive Officer)inMagnus Ivarsson(Chief Scientific Officer)inHannah Pearce(Chief Operating Officer)inMichelle L. Mellion(Chief Medical Officer)in

Co-investorsBrandon Capital Dementia Discovery Fund MPM BioImpact SV Health Investors UCL Technology Fund AlbionVC

Tagworks Pharmaceuticalstagworkspharma.com in 𝕏Series A · Jun 2023 · $65M

Tagworks Pharmaceuticals develops cancer therapies using its Click-to-Release platform, a chemical reaction that activates antibody-drug conjugates (ADCs), masked immunomodulators, and other prodrugs on-target while deactivating radioimmunotherapies off-target.

BiotechHealthtechMedical DevicesNijmegen, NL

Co-investorsBif Lightstone Ventures New Enterprise Associates (NEA)Ysios Capital Clarus Ventures Gilde Healthcare +1 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.